CTLA4 and cancer: In 2011, the first immune checkpoint inhibitor (ipilimumab as an anti-CTLA-4 antibody) was approved by the FDA as for the treatment of melanoma that crated a footstep in immunotherapy cancer treatment (Lipson and Drake, 2011; Sondak et al., 2011; Barbee et al., 2015).